Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Apellis Pharmaceuticals, Inc.”

24 pharma patents match "Apellis Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 24
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 24 pharmaceutical patents matching "Apellis Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

24 results for “Apellis Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 12290566

    Dosing regimens and related compositions and methods

    Apellis Pharmaceuticals, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  2. US 12251395

    RNAS for complement inhibition

    Apellis Pharmaceuticals, Inc. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  3. US 11903994

    Dosing regimens

    Apellis Pharmaceuticals, Inc. · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  4. US 11844841

    Dosing regimens and related compositions and methods

    Apellis Pharmaceuticals, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  5. US 11712460

    Methods of treating chronic disorders with complement inhibitors

    Apellis Pharmaceuticals, Inc. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  6. US 11661441

    Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

    Apellis Pharmaceuticals, Inc. · Granted May 30, 2023 · Expires May 25, 2043

    granted
  7. US 11510939

    RNAs for complement inhibition

    Apellis Pharmaceuticals, Inc. · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted
  8. US 11407789

    Cell-penetrating compstatin analogs and uses thereof

    Apellis Pharmaceuticals, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  9. US 11338013

    Combination therapy for C3 inhibition

    Apellis Pharmaceuticals, Inc. · Granted May 24, 2022 · Expires May 19, 2042

    granted
  10. US 11291407

    Detection of high risk drusen

    Apellis Pharmaceuticals, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  11. US 11292815

    Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods

    Apellis Pharmaceuticals, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  12. US 11040107

    Dosing regimens and related compositions and methods

    Apellis Pharmaceuticals, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted
  13. US 11013782

    Methods of treating chronic disorders with complement inhibitors

    Apellis Pharmaceuticals, Inc. · Granted May 25, 2021 · Expires May 20, 2041

    granted
  14. US 11001610

    Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

    Apellis Pharmaceuticals, Inc. · Granted May 11, 2021 · Expires May 6, 2041

    granted
  15. US 10941184

    Cell-penetrating compstatin analogs and uses thereof

    Apellis Pharmaceuticals, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  16. US 10875893

    Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods

    Apellis Pharmaceuticals, Inc. · Granted Dec 29, 2020 · Expires Dec 24, 2040

    granted
  17. US 10696718

    Compstatin analogs for treatment of neuropathic pain

    Apellis Pharmaceuticals, Inc. · Granted Jun 30, 2020 · Expires Jun 25, 2040

    granted
  18. US 10407466

    Methods of selecting compstatin mimetics

    Apellis Pharmaceuticals, Inc. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  19. US 10308687

    Cell-penetrating compstatin analogs and uses thereof

    Apellis Pharmaceuticals, Inc. · Granted Jun 4, 2019 · Expires May 30, 2039

    granted
  20. US 10125171

    Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

    Apellis Pharmaceuticals, Inc. · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted
  21. US 10039802

    Methods of treating chronic disorders with complement inhibitors

    Apellis Pharmaceuticals, Inc. · Granted Aug 7, 2018 · Expires Aug 2, 2038

    granted
  22. US 10035822

    Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods

    Apellis Pharmaceuticals, Inc. · Granted Jul 31, 2018 · Expires Jul 26, 2038

    granted
  23. US 9421240

    Compstatin analogs for treatment of neuropathic pain

    Apellis Pharmaceuticals, Inc. · Granted Aug 23, 2016 · Expires Aug 18, 2036

    granted
  24. US 8580735

    Local complement inhibition for treatment of complement-mediated disorders

    Apellis Pharmaceuticals, Inc. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted